First-line (off license use) for the treatment of psychosis or for persistent aggression in dementia in line with Antipsychotic Use for Behavioural and Psychiatric Symptoms of Dementia Prescribing Guidance. Prescribing Points October 2011. For details please email OCCG.medicines@nhs.net.
Second-line (off license use) for short term use in line with Antipsychotic Use for Behavioural and Psychiatric Symptoms of Dementia Prescribing Guidance. Prescribing Points October 2011. For details please email OCCG.medicines@nhs.net.
APCO September 2011.
Aripiprazole (Tablet)
Formulary
For moderate to severe manic episodes in adolescents with bipolar disorder.
APCO September 2013.
Suitable for continuation in primary care following specialist initiation for schizophrenia in people aged 15 to 17 years.
Second-line (off license use) for short term use in line with Antipsychotic Use for Behavioural and Psychiatric Symptoms of Dementia Prescribing Guidance. Prescribing Points October 2011. For details please email OCCG.medicines@nhs.net.
For prescribing by Mental Health Specialists only.
APCO September 2017.
Lurasidone
Formulary
For schizophrenia.
Lurasidone is OFF-LABEL for bipolar depression. Any OH prescriber wishing to use lurasidone for this indication should complete an off-label request form and send it to the Drugs and Therapeutics Group (dtc@oxfordhealth.nhs.uk).
Second-line (off license use) for short term use in line with Antipsychotic Use for Behavioural and Psychiatric Symptoms of Dementia Prescribing Guidance. Prescribing Points October 2011. For details please email OCCG.medicines@nhs.net.
ORODISPERSIBLE TABLETS are restricted for palliative or end of life care patients with swallowing difficulties and for patients with feeding tubes only.
Second-line (off license use) for short term use in line with Antipsychotic Use for Behavioural and Psychiatric Symptoms of Dementia Prescribing Guidance. Prescribing Points October 2011. For details please email OCCG.medicines@nhs.net.
APCO September 2011.
For generalised anxiety disorder due to limited evidence suggesting no greater efficacy than antidepressants.
Used in secondary care to initiate treatment. Secondary care will switch to standard release preparation following titration and prior to discharge to primary care.
No clinical evidence of increased tolerability compared to immediate release therapy. Licensing for immediate release and modified release same. Only anecdotal evidence of benefit in titration.
Olanzapine IM is not licensed in the UK. Unlicensed preparations are available.
....
Non Formulary Items
Ziprasidone (Zeldox®)
Non Formulary
Unlicensed in the UK.
Zotepine (Zoleptil®)
Non Formulary
Key
Notes
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Restricted Drug
Unlicensed
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
CCG
Traffic Light Status Information
Status
Description
Red: Medicines which should only be prescribed in secondary care by a specialist.
Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.
Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).
Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.
Brown: Medicines which should only be prescribed in restricted circumstances.
Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.
First choice treatment in psychosis and schizophrenia. Suitable for continuation in primary care following specialist recommendation in line with 
First-line (off license use) for the treatment of psychosis or for persistent aggression in dementia in line with
For moderate to severe manic episodes in adolescents with bipolar disorder.
Suitable for continuation in primary care following specialist recommendation in line with 
Second-line (off license use) for short term use in line with 
For generalised anxiety disorder due to limited evidence suggesting no greater efficacy than antidepressants.
Unlicensed
